<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//TaxonX//DTD Taxonomic Treatment Publishing DTD v0 20100105//EN" "../../nlm/tax-treatment-NS0.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:tp="http://www.plazi.org/taxpub" article-type="research-article" dtd-version="3.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">87</journal-id>
      <journal-id journal-id-type="index">urn:lsid:arphahub.com:pub:A116C711-4C18-5A38-8F1E-5E97753A8A64</journal-id>
      <journal-title-group>
        <journal-title xml:lang="en">Folia Medica</journal-title>
        <abbrev-journal-title xml:lang="en">FM</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0204-8043</issn>
      <issn pub-type="epub">1314-2143</issn>
      <publisher>
        <publisher-name>Plovdiv Medical University</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3897/folmed.64.e68365</article-id>
      <article-id pub-id-type="publisher-id">68365</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
        <subj-group subj-group-type="scientific_subject">
          <subject>Immunology</subject>
          <subject>Oncology</subject>
          <subject>Pharmacology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A concise review of inflammatory biomarkers targeted cancer therapy</article-title>
      </title-group>
      <contrib-group content-type="authors">
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Shah</surname>
            <given-names>Ashish</given-names>
          </name>
          <email xlink:type="simple">shah_ashishpharmacy@yahoo.co.in</email>
          <uri content-type="orcid">https://orcid.org/0000-0003-0817-5940</uri>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Chhagan</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
      </contrib-group>
      <aff id="A1">
        <label>1</label>
        <addr-line content-type="verbatim">Department of Pharmacy, Sumandeep Vidyapeeth, Vadodara, Gujarat, India</addr-line>
        <institution>Department of Pharmacy, Sumandeep Vidyapeeth</institution>
        <addr-line content-type="city">Vadodara</addr-line>
        <country>India</country>
      </aff>
      <aff id="A2">
        <label>2</label>
        <addr-line content-type="verbatim">Gujarat Technological University, Ahmedabad, India</addr-line>
        <institution>Gujarat Technological University</institution>
        <addr-line content-type="city">Ahmedabad</addr-line>
        <country>India</country>
      </aff>
      <aff id="A3">
        <label>3</label>
        <addr-line content-type="verbatim">Shree Sarvajanik Pharmacy College, Mehsana, India</addr-line>
        <institution>Shree Sarvajanik Pharmacy College</institution>
        <addr-line content-type="city">Mehsana</addr-line>
        <country>India</country>
      </aff>
      <author-notes>
        <fn fn-type="corresp">
          <p>Corresponding author: Ashish Shah, Department of Pharmacy, Sumandeep Vidyapeeth, Vadodara, Gujarat, India; Email: <email xlink:type="simple">shah_ashishpharmacy@yahoo.in</email></p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2022</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>31</day>
        <month>08</month>
        <year>2022</year>
      </pub-date>
      <volume>64</volume>
      <issue>4</issue>
      <fpage>572</fpage>
      <lpage>580</lpage>
      <uri content-type="arpha" xlink:href="http://openbiodiv.net/BFC38C74-531D-51E1-BFAB-E30CDEF86C92">BFC38C74-531D-51E1-BFAB-E30CDEF86C92</uri>
      <history>
        <date date-type="received">
          <day>06</day>
          <month>05</month>
          <year>2021</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>08</month>
          <year>2021</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Ashish Shah, Chhagan Patel</copyright-statement>
        <license license-type="creative-commons-attribution" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <label>Abstract</label>
        <p>Inflammation is considered a general protective reaction of localized tissue against injury, irritation, or swelling. Inflammation may be acute, which is part of the defensive response; or chronic, which may lead to the development of various diseases including cancer. Several pro-inflammatory genes play important role in the various cellular processes like cell proliferation, angiogenesis, metastasis, and suppression of apoptosis. These pro-inflammatory genes include <abbrev xlink:title="tumor necrosis factor" id="ABBRID0ELD">TNF</abbrev>-α, interleukins, chemokines, MMPs, cyclooxygenase, lipoxygenase, <abbrev xlink:title="inducible nitric oxide synthase" id="ABBRID0EPD">iNOS</abbrev>, Jak/<abbrev xlink:title="signal transducer and activator of transcription protein" id="ABBRID0ETD">STAT</abbrev> pathway, etc. All these genes are mainly regulated by the transcription factor NF-κB, which is found active in many types of neoplastic cells. Therefore, developing molecules that target pro-inflammatory genes or transcription factor is believed to be one of the good strategies for development of anti-cancer agents. Literature data suggest that many anti-inflammatory agents, including non-steroidal anti-inflammatory drugs, corticosteroids, statins, metformin, embelin, and some natural products, can interfere with the tumor microenvironment by inhibiting pro-inflammatory genes or transcription factors and increasing cell apoptosis. This review describes the link between inflammation and cancer, the role of pro-inflammatory genes and transcription factors in the development of tumor cells, and the use of anti-inflammatory agents in cancer.</p>
      </abstract>
      <kwd-group>
        <label>Keywords</label>
        <kwd>anti-inflammatory agents</kwd>
        <kwd>cancer</kwd>
        <kwd>cancer prevention</kwd>
        <kwd>inflammation</kwd>
        <kwd>inflammatory biomarkers</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="List of abbreviations" id="SECID0E6D">
      <title>List of abbreviations</title>
      <p><bold><abbrev xlink:title="tumor necrosis factor" id="ABBRID0EHE">TNF</abbrev></bold>: tumor necrosis factor;</p>
      <p><bold><abbrev xlink:title="cyclooxygenase" id="ABBRID0EQE">COX</abbrev></bold>: cyclooxygenase;</p>
      <p><bold><abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EZE">IL</abbrev></bold>: interlukins;</p>
      <p><bold><abbrev xlink:title="" id="ABBRID0ECF">MMPs</abbrev></bold>: matrix metalloproteinases;</p>
      <p><bold><abbrev xlink:title="lipooxygenase" id="ABBRID0ELF">LOX</abbrev></bold>: lipooxygenase;</p>
      <p><bold><abbrev xlink:title="inducible nitric oxide synthase" id="ABBRID0EUF">iNOS</abbrev></bold>: inducible nitric oxide synthase;</p>
      <p><bold><abbrev xlink:title="hypoxia inducible factor" id="ABBRID0E4F">HIF</abbrev></bold>: hypoxia inducible factor;</p>
      <p><bold><abbrev xlink:title="phosphoinositide-3-Kinase" id="ABBRID0EGG">PI3K</abbrev></bold>: phosphoinositide-3-Kinase;</p>
      <p><bold><abbrev xlink:title="mitogen activated protein kinase" id="ABBRID0EPG">MAPK</abbrev></bold>: mitogen activated protein kinase;</p>
      <p><bold><abbrev xlink:title="prostaglandin" id="ABBRID0EWG">PG</abbrev></bold>: prostaglandin; </p>
      <p><bold><abbrev xlink:title="vascular endothelial growth factor" id="ABBRID0E5G">VEGF</abbrev></bold>: vascular endothelial growth factor;</p>
      <p><bold><abbrev xlink:title="janus kinase" id="ABBRID0EHH">JAK</abbrev></bold>: janus kinase;</p>
      <p><bold><abbrev xlink:title="signal transducer and activator of transcription protein" id="ABBRID0EQH">STAT</abbrev></bold>: signal transducer and activator of transcription protein;</p>
      <p><bold><abbrev xlink:title="phosphoinositide-3-kinase" id="ABBRID0EZH">PI3K</abbrev></bold>: phosphoinositide-3-kinase;</p>
      <p><bold><abbrev xlink:title="squamous cell carcinoma" id="ABBRID0EDAAC">SCC</abbrev></bold>: squamous cell carcinoma;</p>
      <p><bold><abbrev xlink:title="non-steroidal anti-inflammatory drugs; HCC: hepatocellular carcinoma" id="ABBRID0EMAAC">NSAIDs</abbrev></bold>: non-steroidal anti-inflammatory drugs; HCC: hepatocellular carcinoma;</p>
      <p><bold><abbrev xlink:title="cyclin-dependent kinases" id="ABBRID0EVAAC">CDK</abbrev></bold>: cyclin-dependent kinases</p>
    </sec>
    <sec sec-type="Introduction" id="SECID0E1AAC">
      <title>Introduction</title>
      <p>In 1863, the first clue between inflammation and cancer was identified by Rudolf Ludwig Carl Virchow that the inflammatory process is one of the conditions for the development of cancer cells.<sup>[<xref ref-type="bibr" rid="B1">1</xref>]</sup> Chronic inflammation triggers the growth of the tumor cells by accelerating the production of growth factors as well as reactive oxygen and nitrogen which interact with DNA and produce mutations. There are different inflammatory modulators like chemokines, cytokines, growth factors, free radicals, prostaglandins, and proteolytic enzymes that favor the development of the tumor cells. These inflammatory modulators are synthesized from different types of cells such as fibroblasts, adipocytes, dendritic cells, natural killer cells, lymphocytes, neutrophils, macrophages, etc. Some of these modulators directly act on tumor cells by supporting proliferation, oncogenic mutation, and inhibiting cell death. Some of the modulators act as prototumorogenic agents, which act on the components of the tumor microenvironment. The inflammation may be acute or chronic. The acute inflammation occurs for a short period as a pyrogenic response which results in the development of a fever for a short period. When inflammation lasts too long, then it can be chronic inflammation, which can be harmful and may lead to a disease.<sup>[<xref ref-type="bibr" rid="B2">2</xref>]</sup> Various epidemiological studies suggest that 20% of all cancers begin as a direct consequence of a chronic inflammatory disease. Inflammation is the common process of various cancer risk factors, which include smoking, alcohol consumption, obesity, several types of infection, etc. <bold>(Fig. <xref ref-type="fig" rid="F1">1</xref>)</bold>. The goal of primary, secondary, or tertiary cancer prevention is to reduce the exposure of risk factors of the cancers. Avoiding exposure to primary carcinogenic factors has the potential to reduce 30% of cancer deaths.<sup>[<xref ref-type="bibr" rid="B3">3</xref>]</sup></p>
      <fig id="F1" position="float" orientation="portrait">
        <object-id content-type="arpha">E3CE16C0-A72E-5745-BC90-42B68F55FAA7</object-id>
        <label>Figure 1.</label>
        <caption>
          <p>Factors that increase the inflammation, types of inflammation and various receptors involved in inflammation, responsible for activation of tumor cells.</p>
        </caption>
        <graphic xlink:href="foliamedica-64-4-e68365-g001.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_744504.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/744504</uri>
        </graphic>
      </fig>
      <p>Prevention of cancer can be possible in two ways; the first is primary prevention by reducing exposure of risk factors of cancer and the second is by immunoprevention and chemoprevention. Immunoprevention aims to control the development (or initiation) of cancer cells by the immune system while the chemopreventive effect focused on suppressing or prevent the conversion of malignant to invasive cancer types. In this review we had discussed, the role of various inflammatory mediators involved in the promotion of tumor which gives an idea about the link between inflammation and cancer and the role of anti-inflammatory agents in the treatment of cancer.<sup>[<xref ref-type="bibr" rid="B4">4</xref>]</sup></p>
    </sec>
    <sec sec-type="Various inflammatory mediators involved in the promotion of tumor" id="SECID0EDCAC">
      <title>Various inflammatory mediators involved in the promotion of tumor</title>
      <p>There are mainly two pathways that link inflammation and cancer: these are the intrinsic pathways and the extrinsic pathways. The first type of pathway is activated by inflammatory stimuli which increase the risk of cancer, and the second is due to genetic mutation which causes inflammation and cancer. This pathway is interconnected through various inflammatory mediators, which include various cytokines, growth factors, and metalloproteases <bold>(Table <xref ref-type="table" rid="T1">1</xref>)</bold> which helps in the development of the tumor microenvironment <bold>(Fig. <xref ref-type="fig" rid="F2">2</xref>)</bold>.</p>
      <table-wrap id="T1" position="float" orientation="portrait">
        <label>Table 1.</label>
        <caption>
          <p>Various inflammatory mediators involved in the promotion of different types of cancer<sup>[3,33]</sup></p>
        </caption>
        <table id="TID0E2NAE" rules="all">
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>Cancer type</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Inflammatory receptor involved</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Breast cancer</td>
              <td rowspan="1" colspan="1">CXCR4, CCR7, <abbrev xlink:title="cyclooxygenase" id="ABBRID0EITAE">COX</abbrev>-2, MMP1, MM9</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Cervical carcinoma</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EUTAE">IL</abbrev>-1α, <abbrev xlink:title="tumor necrosis factor" id="ABBRID0EYTAE">TNF</abbrev>, <abbrev xlink:title="cyclooxygenase" id="ABBRID0E3TAE">COX</abbrev>-1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Ovarian tumors</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="tumor necrosis factor" id="ABBRID0EIUAE">TNF</abbrev>, <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EMUAE">IL</abbrev>-8, CXCR4/CXCL12, CXCR4, SDF1, <abbrev xlink:title="cyclooxygenase" id="ABBRID0EQUAE">COX</abbrev>-2, <abbrev xlink:title="inducible nitric oxide synthase" id="ABBRID0EUUAE">iNOS</abbrev></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Glioma</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="tumor necrosis factor" id="ABBRID0E6UAE">TNF</abbrev>, <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EDVAE">IL</abbrev>-8, <abbrev xlink:title="cyclooxygenase" id="ABBRID0EHVAE">COX</abbrev>-2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Prostate cancer</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="matrix metalloproteinases" id="ABBRID0ETVAE">IL</abbrev>-8, CXCL14, <abbrev xlink:title="cyclooxygenase" id="ABBRID0EXVAE">COX</abbrev>-2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Melanoma</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EDWAE">IL</abbrev>-8, <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EHWAE">IL</abbrev>-18, CXCR4, CCR7, CCR10, <abbrev xlink:title="cyclooxygenase" id="ABBRID0ELWAE">COX</abbrev>-2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Oesophageal adenocarcinoma</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="cyclooxygenase" id="ABBRID0EXWAE">COX</abbrev>-2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Oesophageal <abbrev xlink:title="squamous cell carcinoma" id="ABBRID0EAXAE">SCC</abbrev> and AC</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="cyclooxygenase" id="ABBRID0EIXAE">COX</abbrev>-2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Urinary bladder</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="cyclooxygenase" id="ABBRID0EUXAE">COX</abbrev>-1, <abbrev xlink:title="cyclooxygenase" id="ABBRID0EYXAE">COX</abbrev>-2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Pancreatic carcinoma</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EEYAE">IL</abbrev>-1α, <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EIYAE">IL</abbrev>-1β, MIP-3α, CCR6, <abbrev xlink:title="cyclooxygenase" id="ABBRID0EMYAE">COX</abbrev>-2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Head and neck <abbrev xlink:title="squamous cell carcinoma" id="ABBRID0EVYAE">SCC</abbrev></td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="cyclooxygenase" id="ABBRID0E3YAE">COX</abbrev>-2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lung carcinoma</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EIZAE">IL</abbrev>-1α, <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EMZAE">IL</abbrev>-1β, <abbrev xlink:title="cyclooxygenase" id="ABBRID0EQZAE">COX</abbrev>-2, CXC, CXCL5, and CXCL8</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Gastric carcinoma</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="matrix metalloproteinases" id="ABBRID0E3ZAE">IL</abbrev>-8, <abbrev xlink:title="cyclooxygenase" id="ABBRID0EA1AE">COX</abbrev>-2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Colorectal cancer</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EM1AE">IL</abbrev>-6, <abbrev xlink:title="cyclooxygenase" id="ABBRID0EQ1AE">COX</abbrev>-2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Brain tumors</td>
              <td rowspan="1" colspan="1">5-<abbrev xlink:title="lipooxygenase" id="ABBRID0E31AE">LOX</abbrev></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Colon cancer</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EH2AE">IL</abbrev>-6 <abbrev xlink:title="cyclooxygenase" id="ABBRID0EL2AE">COX</abbrev>-2, 5LOX, MMP7</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Skin cancer</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="tumor necrosis factor" id="ABBRID0EX2AE">TNF</abbrev>, 5LOX, MMP9</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Bladder cancer</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="matrix metalloproteinases" id="ABBRID0ED3AE">IL</abbrev>-6</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Renal cell carcinoma</td>
              <td rowspan="1" colspan="1"><abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EP3AE">IL</abbrev>-6, CCR3</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Leukemia</td>
              <td rowspan="1" colspan="1">
                <abbrev xlink:title="tumor necrosis factor" id="ABBRID0E23AE">TNF</abbrev>
              </td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="F2" position="float" orientation="portrait">
        <object-id content-type="arpha">E8DFE867-E622-53E9-9F21-502F01B5F01B</object-id>
        <label>Figure 2.</label>
        <caption>
          <p>Various inflammatory targets that provide link between inflammation and cancer by involving in various stages of cancer cell development process.</p>
        </caption>
        <graphic xlink:href="foliamedica-64-4-e68365-g002.jpg" position="float" orientation="portrait" xlink:type="simple" id="oo_744505.jpg">
          <uri content-type="original_file">https://binary.pensoft.net/fig/744505</uri>
        </graphic>
      </fig>
      <sec sec-type="TNF-alpha" id="SECID0EXCAC">
        <title><abbrev xlink:title="tumor necrosis factor" id="ABBRID0E3CAC">TNF</abbrev>-alpha</title>
        <p><abbrev xlink:title="tumor necrosis factor" id="ABBRID0ECDAC">TNF</abbrev>-alpha is a multicellular kinase that plays important role in various cellular events like cell differentiation, survival, and death. There are two types of this receptor; the first is TNFR1 that is expressed all over the cell and the second is TNFR2, which is expressed mainly in the immune cells. TNFR1 receptor contains the intracellular domain, the transmembrane domain, an extracellular domain, and it is considered as one of the important members of the death receptor family as it is mainly involved in the cell death program. Due to this, it is also considered a death domain (DD) receptor. TNFR2 does not contain the DD domain - its action mediates through TNFR1.<sup>[<xref ref-type="bibr" rid="B5">5</xref>]</sup> The biological function of <abbrev xlink:title="tumor necrosis factor" id="ABBRID0ENDAC">TNF</abbrev> executes through activating several signaling pathways like NF-κB and c-Jun N-terminal kinase (JNK). NF-κB produces a cell survival signal that produces an anti-apoptosis effect. There are various approaches like transgenic models, gene deletion, and use of antibodies that have been adopted to check the role of <abbrev xlink:title="tumor necrosis factor" id="ABBRID0ERDAC">TNF</abbrev>-alpha in cancer. Data suggest that this receptor has an important role in the development of malignant cells. In the skin cancer study, it was found that TNFR1 mediated signaling activates NF-κB; which provides signals that help tumor cells to escape from apoptosis.<sup>[<xref ref-type="bibr" rid="B6">6</xref>]</sup></p>
      </sec>
      <sec sec-type="Interleukins" id="SECID0E2DAC">
        <title>Interleukins</title>
        <p>Interleukins functioned like intercellular hormones that can alter cellular functions. There are several types of interleukins (<abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EBEAC">IL</abbrev>) that include <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EFEAC">IL</abbrev>-1, <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EJEAC">IL</abbrev>-6, <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0ENEAC">IL</abbrev>-8, and <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EREAC">IL</abbrev>-18 which play an important role in cancer development. <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EVEAC">IL</abbrev>-1α promotes cervical carcinoma and also induces anchorage independence in embryo fibroblasts. <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EZEAC">IL</abbrev>-1β also increases the cancer cell growth and is mainly associated with the development of chemoresistance in pancreatic carcinoma.‌<sup>[<xref ref-type="bibr" rid="B7">7</xref>]</sup> Production of <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EEFAC">IL</abbrev>-6 is linked with p53; upon mutation of p53 produce a higher level of <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EIFAC">IL</abbrev>-6 and mainly involved in the cancers like multiple myeloma, non-Hodgkin’s lymphoma, bladder cancer, colorectal cancer, and renal cell carcinoma (RCC).‌<sup>[<xref ref-type="bibr" rid="B8">8</xref>]</sup> Cytokine <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0ETFAC">IL</abbrev>-8 has been reported to promote growth and metastasis of a wide variety of tumors. For tumor-associated inflammation, Ras-dependent <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EXFAC">IL</abbrev>-6 production is required. Expression of <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0E2FAC">IL</abbrev>-8 by human melanoma cells and human ovarian cancer cells correlates with their metastatic potential. <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0E6FAC">IL</abbrev>-8 has been detected in astrocytoma, anaplastic astrocytoma, glioblastomas, and central nervous system cervical carcinoma metastasis.<sup>[<xref ref-type="bibr" rid="B9">9</xref>]</sup></p>
      </sec>
      <sec sec-type="Chemokines" id="SECID0EJGAC">
        <title>Chemokines</title>
        <p>The chemokines family has four different members, which, based on the cysteine residues are classified as C, CC, CX3C, and CXC. Chemokines play either beneficial or non-beneficial role for cancer patients. Recruitment of mature dendritic and/or effectors cell provide beneficial effect while chemokine mediated recruitment of immature dendritic cell can increase tumor cell tolerance. In cancer cell development, chemokines play important role in the process like angiogenesis, inflammation, cell migration, etc.<sup>[<xref ref-type="bibr" rid="B10">10</xref>]</sup> The main role of chemokines in inflammation is to traffic leucocytes to the inflammation site. CC chemokines play an important role in the macrophage and lymphocyte infiltration in melanoma and carcinoma associated with different cancers such as ovary, breast, cervix, and glioma. The concentration of chemokine receptor CXC4 and CCR7 was found higher in breast cancers. CXC play important role in inflammation, wound healing, cellular cycle regulation, angiogenesis, tumorigenesis, etc. The presence of CXCR4 was found in ovarian cancer while upregulation of CCR4 was found in renal cell carcinoma. CXCR4 activates EGFR in ovarian cancer.<sup>[<xref ref-type="bibr" rid="B11">11</xref>]</sup></p>
      </sec>
      <sec sec-type="Matrix metalloproteinases (MMPs)" id="SECID0E3GAC">
        <title>Matrix metalloproteinases (MMPs)</title>
        <p>Matrix metalloproteins are involved in various biological processes like inflammation, wound healing, cellular migration, skeletal formation, and cancer. MMP9 upregulation is found in various stages of tumorigenesis. MMP9 transferred by bone marrow plays a crucial role in skin carcinogens; supported by the evidence that transgenic mice lacking MMP9 have reduced hyperproliferation and invasiveness.<sup>[<xref ref-type="bibr" rid="B12">12</xref>]</sup> In a breast cancer patient, 70 genes are identified for their poor prognosis; out of those two genes are MMP-1 and MMP-9. In a recent study, it was found that out of the 95 genes, MMP1 is the second most important gene which has the potential of breast cancer to produce lung metastases.<sup>[<xref ref-type="bibr" rid="B13">13</xref>]</sup></p>
      </sec>
      <sec sec-type="Cyclooxygenase (COX)" id="SECID0EPHAC">
        <title>Cyclooxygenase (<abbrev xlink:title="cyclooxygenase" id="ABBRID0EUHAC">COX</abbrev>)</title>
        <p>There are three isoforms of <abbrev xlink:title="cyclooxygenase" id="ABBRID0E1HAC">COX</abbrev> that have been identified: A) <abbrev xlink:title="cyclooxygenase" id="ABBRID0E5HAC">COX</abbrev>-1 is mainly involved in tissue homeostasis, platelet aggregation, renal blood flow, and maintenance of gastric mucosa, B) <abbrev xlink:title="cyclooxygenase" id="ABBRID0ECIAC">COX</abbrev>-2 is found in inflamed and neoplastic tissues, and C) <abbrev xlink:title="cyclooxygenase" id="ABBRID0EGIAC">COX</abbrev>-3 is mainly expressed in the brain and spinal cord. The <abbrev xlink:title="cyclooxygenase" id="ABBRID0EKIAC">COX</abbrev> pathway by PGH2 synthetase produces PGG2, which is unstable, and PGH2 in the presence of PGH2 synthase and peroxidase enzyme. This converts into various PGs and TxA2. <abbrev xlink:title="cyclooxygenase" id="ABBRID0EOIAC">COX</abbrev>-2 level in cancer can be elevated by cytokines, growth oncogene, and other factors. <abbrev xlink:title="cyclooxygenase" id="ABBRID0ESIAC">COX</abbrev>-2 is responsible for the development and growth of a variety of cancers.<sup>[<xref ref-type="bibr" rid="B14">14</xref>]</sup> The expression of <abbrev xlink:title="cyclooxygenase" id="ABBRID0E4IAC">COX</abbrev>-2 is regulated by NF-κB. In colon carcinoma, the <abbrev xlink:title="cyclooxygenase" id="ABBRID0EBJAC">COX</abbrev> enzyme induces angiogenesis in two ways; the first way is modulation of angiogenic factors by <abbrev xlink:title="cyclooxygenase" id="ABBRID0EFJAC">COX</abbrev>-2 and <abbrev xlink:title="cyclooxygenase" id="ABBRID0EJJAC">COX</abbrev>-1 regulates angiogenesis in endothelial cells.<sup>[<xref ref-type="bibr" rid="B15">15</xref>]</sup><abbrev xlink:title="cyclooxygenase" id="ABBRID0EUJAC">COX</abbrev>-2 was found at a higher level in epithelial cells of invasive breast cancer. <abbrev xlink:title="cyclooxygenase" id="ABBRID0EYJAC">COX</abbrev>-2 also plays an important role in the growth of human lung adenocarcinoma. The physiological effect of PGs and TXA2 is mediated through G protein-coupled proteinoid receptors which are divided into nine different types. PGE2 gives biological response through four different receptors; EP1 to EP4. EP4 modulate PGE2, which is involved in the proliferation of colon cancer cells.<sup>[<xref ref-type="bibr" rid="B16">16</xref>]</sup> Around 93% of melanomas are expressed with <abbrev xlink:title="cyclooxygenase" id="ABBRID0EDKAC">COX</abbrev>-2 with an expression ratio of around 68%. This overexpression plays important role in the development and growth of malignant epithelial cancer cells. In the pathogenesis of oesophageal cancer, involvement of both <abbrev xlink:title="cyclooxygenase" id="ABBRID0EHKAC">COX</abbrev>-1 and <abbrev xlink:title="cyclooxygenase" id="ABBRID0ELKAC">COX</abbrev>-2 have been detected due to their link with <abbrev xlink:title="vascular endothelial growth factor" id="ABBRID0EPKAC">VEGF</abbrev>-A and <abbrev xlink:title="vascular endothelial growth factor" id="ABBRID0ETKAC">VEGF</abbrev>-C, which are important modulators of angiogenesis.<sup>[<xref ref-type="bibr" rid="B17">17</xref>]</sup></p>
      </sec>
      <sec sec-type="Lipoxygenase" id="SECID0E4KAC">
        <title>Lipoxygenase</title>
        <p>The metabolic process for conversion of arachidonic acid to leukotrienes requires the presence of a 5-lipoxygenase enzyme which is the key factor for this metabolic process. Leukotrienes play important role in some allergic and inflammatory conditions. Apart from that, they are also involved in the pathophysiological functions of the brain like cerebral ischemia, brain edema, and increase the permeability of the blood-brain barrier in brain tumors.<sup>[<xref ref-type="bibr" rid="B18">18</xref>]</sup> In the nude mice xenograft model treated with colon cancer with cigarette smoke extract, the inhibition of the enzymes <abbrev xlink:title="cyclooxygenase" id="ABBRID0EKLAC">COX</abbrev>-2 and 5-<abbrev xlink:title="lipooxygenase" id="ABBRID0EOLAC">LOX</abbrev> reduces the tumor size.<sup>[<xref ref-type="bibr" rid="B19">19</xref>]</sup> The evidence is further confirmed by the experiment in which cigarettes smoke without filter increases the expression of 5-<abbrev xlink:title="lipooxygenase" id="ABBRID0EZLAC">LOX</abbrev>. This overexpression stimulates MMP and <abbrev xlink:title="vascular endothelial growth factor" id="ABBRID0E4LAC">VEGF</abbrev>, which are key factors in the angiogenesis process. 5-<abbrev xlink:title="lipooxygenase" id="ABBRID0EBMAC">LOX</abbrev> inhibitors decrease the colon adenoma formation and also decrease the expression of <abbrev xlink:title="vascular endothelial growth factor" id="ABBRID0EFMAC">VEGF</abbrev> and MMP in tumor cells, ultimately the angiogenesis rate will be decreased.<sup>[<xref ref-type="bibr" rid="B20">20</xref>]</sup></p>
      </sec>
      <sec sec-type="NF-κB" id="SECID0EPMAC">
        <title>NF-κB</title>
        <p>Regulation of <abbrev xlink:title="tumor necrosis factor" id="ABBRID0EVMAC">TNF</abbrev>, <abbrev xlink:title="cyclooxygenase" id="ABBRID0EZMAC">COX</abbrev>, <abbrev xlink:title="lipooxygenase" id="ABBRID0E4MAC">LOX</abbrev>, and MMPs is done by the transcription factor NF-κB which is normally present in an inactivated state in most cells, but in cancer cells, NF-κB is found as active. The activation of NF-κB induces inflammation and tumorigenesis.<sup>[<xref ref-type="bibr" rid="B21">21</xref>]</sup> The activation of the NF-κB response is triggered in the presence of pro-inflammatory cytokines and infectious agents. NF-κB heterodimer is trapped in the cytoplasm when it is bound to IkB, which, upon phosphorylation induces the cytokines, which results in activation of NF-κB. It has been found that in inflammation, the response of NF-κB is triggered through <abbrev xlink:title="tumor necrosis factor" id="ABBRID0EINAC">TNF</abbrev>-α which produces anti-apoptosis signals. By enhancing the signaling of NF-κB, cancer cells increase invasiveness. Cancer-associated <abbrev xlink:title="tumor necrosis factor" id="ABBRID0EMNAC">TNF</abbrev>-α overexpression; inhibition of <abbrev xlink:title="tumor necrosis factor" id="ABBRID0EQNAC">TNF</abbrev>-α suppresses the response of NF-κB and by this way produces apoptosis process.<sup>[<xref ref-type="bibr" rid="B22">22</xref>]</sup> In the last few decades, extensive research has been going on NF-κB, and it was found that over-production of this receptor increases the resistance of chemotherapy as well as γ-radiation therapy. Inhibition of NF-κB can sensitize the cancer cells and therefore NF-κB is considered as one of the important targets for the development of chemotherapeutic agents.<sup>[<xref ref-type="bibr" rid="B23">23</xref>]</sup></p>
      </sec>
      <sec sec-type="Hypoxia-inducible factor-1 (HIF-1)" id="SECID0EBOAC">
        <title>Hypoxia-inducible factor-1 (<abbrev xlink:title="hypoxia inducible factor" id="ABBRID0EGOAC">HIF</abbrev>-1)</title>
        <p>Hypoxia-inducible factor contains two subunit alpha and beta; receptor present in the heterodimeric complex. The alpha subunit is less stable as compared to the beta subunit. Recent literature data have shown that inflammation (via inflammatory mediators) can also activate <abbrev xlink:title="hypoxia inducible factor" id="ABBRID0EMOAC">HIF</abbrev>-1 in normoxic conditions.<sup>[<xref ref-type="bibr" rid="B24">24</xref>]</sup> Various cytokines, hormones can increase the expression of <abbrev xlink:title="hypoxia inducible factor" id="ABBRID0EXOAC">HIF</abbrev>-1. Cytokines such as <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0E2OAC">IL</abbrev>-1β and <abbrev xlink:title="tumor necrosis factor" id="ABBRID0E6OAC">TNF</abbrev>-α were reported for stimulation of <abbrev xlink:title="hypoxia inducible factor" id="ABBRID0EDPAC">HIF</abbrev>-1α expression. <abbrev xlink:title="hypoxia inducible factor" id="ABBRID0EHPAC">HIF</abbrev>-1α can stimulate the expression of several genes that includes, <abbrev xlink:title="cyclooxygenase" id="ABBRID0ELPAC">COX</abbrev>-2, <abbrev xlink:title="inducible nitric oxide synthase" id="ABBRID0EPPAC">iNOS</abbrev>, vascular endothelial growth factor receptor (<abbrev xlink:title="vascular endothelial growth factor" id="ABBRID0ETPAC">VEGF</abbrev>), glucose transporter, etc.<sup>[<xref ref-type="bibr" rid="B7">7</xref>]</sup> Overactivation of <abbrev xlink:title="hypoxia inducible factor" id="ABBRID0E5PAC">HIF</abbrev>-1α has been demonstrated in various types of cancer as it provides favorable conditions for the development and growth of tumor cells.<sup>[<xref ref-type="bibr" rid="B25">25</xref>]</sup></p>
      </sec>
      <sec sec-type="Inducible nitric oxide synthase (iNOS)" id="SECID0EJAAE">
        <title>Inducible nitric oxide synthase (<abbrev xlink:title="inducible nitric oxide synthase" id="ABBRID0EOAAE">iNOS</abbrev>)</title>
        <p>There are three different enzymes required for the synthesis of nitric oxide and <abbrev xlink:title="inducible nitric oxide synthase" id="ABBRID0EUAAE">iNOS</abbrev> is one of them. Cytokines like <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EYAAE">IL</abbrev>-1β, <abbrev xlink:title="tumor necrosis factor" id="ABBRID0E3AAE">TNF</abbrev>-α, and IFN-γ can stimulate this enzyme. The expression of <abbrev xlink:title="inducible nitric oxide synthase" id="ABBRID0EABAE">iNOS</abbrev> is regulated by transcription factors including NF-kB, activator protein 1, signal transducer and activator of transcription, 1α interferon regulatory protein 1, nuclear factor interleukin-6, and high motility group I (γ) protein.<sup>[<xref ref-type="bibr" rid="B26">26</xref>]</sup><abbrev xlink:title="inducible nitric oxide synthase" id="ABBRID0ELBAE">iNOS</abbrev> mediated cellular changes can produce malignancy, metastasis, angiogenesis of cancer cells which is involved in a variety of cancer types such as melanoma, prostate, bladder, and colorectal cancer.<sup>[<xref ref-type="bibr" rid="B27">27</xref>]</sup></p>
      </sec>
      <sec sec-type="Jak/STAT pathway" id="SECID0EVBAE">
        <title>Jak/<abbrev xlink:title="signal transducer and activator of transcription protein" id="ABBRID0E1BAE">STAT</abbrev> pathway</title>
        <p><abbrev xlink:title="signal transducer and activator of transcription protein" id="ABBRID0EACAE">STAT</abbrev> family includes seven members, which are involved in different cellular processes like survival, cell proliferation, and angiogenesis. Out of the seven members, the important member involved in cancer is the STAT3 transcription factor. The expression of STAT3 is stimulated mainly by IL6, <abbrev xlink:title="matrix metalloproteinases" id="ABBRID0EECAE">IL</abbrev>-11, and other members of the cytokine family as well as growth factors. Upon activation, STAT3 phosphorylation followed by homodimerization occurs. This dimer shift into the nucleus binds with DNA and stimulates the transcription of some genes involved in oncogenic activation such as Bcl-2, CDK1, <abbrev xlink:title="vascular endothelial growth factor" id="ABBRID0EICAE">VEGF</abbrev>, etc. Due to this STAT3 is found highly expressed in several cancers like multiple myeloma, leukemia, prostate cancer, lymphoma, breast cancer, squamous cell carcinoma of the head and neck.<sup>[<xref ref-type="bibr" rid="B28">28</xref>]</sup></p>
      </sec>
      <sec sec-type="Other pathways" id="SECID0ESCAE">
        <title>Other pathways</title>
        <p>The other pathways which are directly or indirectly activated by inflammation or inflammatory receptors include mitogen-activated protein kinase (<abbrev xlink:title="mitogen activated protein kinase" id="ABBRID0EYCAE">MAPK</abbrev>), phosphoinositide-3-kinase (<abbrev xlink:title="phosphoinositide-3-Kinase" id="ABBRID0E3CAE">PI3K</abbrev>), CREB signaling pathway, and Wnt/beta-catenin pathway. MAPKs are involved in various cellular processes like cell growth, differentiation, survival, and various immune and stress-related responses.<sup>[<xref ref-type="bibr" rid="B29">29</xref>]</sup> It is mainly activated and regulated by various cytokines through the phosphorylation process. <abbrev xlink:title="phosphoinositide-3-Kinase" id="ABBRID0EHDAE">PI3K</abbrev> is mainly involved in the immune response of cancer cells and is found highly expressed in pancreatic cancer due to mutation of K-Ras in the patient with pancreatic cancer.<sup>[<xref ref-type="bibr" rid="B30">30</xref>]</sup> CREB plays an important role in cell survival, differentiation of neurons, and metabolism. The process like reverse phosphorylation of serine by various kinase can increase the transcription activity of CREB. The high expression of CREB is found in various types of cancer which includes myeloid leukaemia, non-small cell lung carcinoma, melanoma, mammary carcinoma, etc.<sup>[<xref ref-type="bibr" rid="B31">31</xref>]</sup> Wnt/beta-catenin pathway is involved in various biological processes like cell polarity, cell proliferation, and cell fate determination during embryonic development and tissue homeostasis. Wnt pathway can interact with many other pathways including <abbrev xlink:title="hypoxia inducible factor" id="ABBRID0EZDAE">HIF</abbrev>-1α, NF-kB, and Notch, stimulate the function of this pathway. Mutation of the Wnt pathway can produce various types of cancer which include cancers of the stomach, liver, intestine, pancreas, and ovaries.<sup>[<xref ref-type="bibr" rid="B32">32</xref>]</sup></p>
      </sec>
    </sec>
    <sec sec-type="Role of anti-inflammatory agents in cancer" id="SECID0EDEAE">
      <title>Role of anti-inflammatory agents in cancer</title>
      <p>Targeting inflammatory pathways involved in tumor promotion can be a good strategy for the prevention of cancer, in this regard preventive and anti-cancer effects of anti-inflammatory drugs can be useful <bold>(Table <xref ref-type="table" rid="T2">2</xref>)</bold>.</p>
      <table-wrap id="T2" position="float" orientation="portrait">
        <label>Table 2.</label>
        <caption>
          <p>Preventive and anti-cancer effects of anti-inflammatory drugs in various types of cancer<sup>[39,46]</sup></p>
        </caption>
        <table id="TID0ETWAE" rules="all">
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>Drug</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Preventive effect on cancer</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Anti-cancer effect</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Aspirin</td>
              <td rowspan="1" colspan="1">Bladder, breast, colorectal, oesophageal, and lung</td>
              <td rowspan="1" colspan="1">Gastric and colon cancer</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Celecoxib</td>
              <td rowspan="1" colspan="1">Bladder, breast, cervix, colorectal, lung, prostate</td>
              <td rowspan="1" colspan="1">Prostate, liver and colon</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Ibuprofen</td>
              <td rowspan="1" colspan="1">Colon adenoma</td>
              <td rowspan="1" colspan="1">Breast cancer</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Sulindac</td>
              <td rowspan="1" colspan="1">Breast cancer</td>
              <td rowspan="1" colspan="1">Colon cancer</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Piroxicam</td>
              <td rowspan="1" colspan="1">Colorectal cancer</td>
              <td rowspan="1" colspan="1">Colon cancer</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Dexamethasone</td>
              <td rowspan="1" colspan="1">Breast and rectal</td>
              <td rowspan="1" colspan="1">Multiple myeloma</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <sec sec-type="Non-steroidal anti-inflammatory drugs" id="SECID0EQEAE">
        <title>Non-steroidal anti-inflammatory drugs</title>
        <p>The main role of NSAIDS as anticancer agents is due to their role of inhibition of COX1/2 enzyme which is required for the biosynthesis of prostaglandins and leukotrienes. The level of PGE2 is elevated in different types of cancer production. They increase cancer cell production by favoring angiogenesis, tumor growth, metastasis, and inhibiting apoptosis. PGE2 can activate several cellular pathways like <abbrev xlink:title="mitogen activated protein kinase" id="ABBRID0EWEAE">MAPK</abbrev>, <abbrev xlink:title="phosphoinositide-3-Kinase" id="ABBRID0E1EAE">PI3K</abbrev>/AKT, and NF-kB which further activates <abbrev xlink:title="vascular endothelial growth factor" id="ABBRID0E5EAE">VEGF</abbrev>, Bcl-2, EGFR, and MMPS and increase the rate of tumorigenesis. The possible mechanism for rational use of aspirin for cancer prevention involved inhibition of various targets like inhibition of COX1/2, certain pro-inflammatory cytokines, modulation on immune response, the effect on <abbrev xlink:title="phosphoinositide-3-Kinase" id="ABBRID0ECFAE">PI3K</abbrev> signaling, maintenance of cancer stem cell homeostasis, and decreased glycolytic rate in cancer cells.<sup>[<xref ref-type="bibr" rid="B34">34</xref>]</sup> The long-term use of <abbrev xlink:title="non-steroidal anti-inflammatory drugs; HCC: hepatocellular carcinoma" id="ABBRID0ENFAE">NSAIDs</abbrev> may lead to the development of several side effects such as renal failure, GI problems such as acidity, ulcer, and intestinal inflammation which cause perforation and strictures in small and large intestines. This factor can also induce the risk of cancer. To reduce the side effect of <abbrev xlink:title="non-steroidal anti-inflammatory drugs; HCC: hepatocellular carcinoma" id="ABBRID0ERFAE">NSAIDs</abbrev>, they can combine with 5-<abbrev xlink:title="lipooxygenase" id="ABBRID0EVFAE">LOX</abbrev> inhibitors so that the synthesis of prostaglandins and leukotrienes are blocked.<sup>[<xref ref-type="bibr" rid="B35">35</xref>]</sup></p>
        <p>The investigation of the link between <abbrev xlink:title="non-steroidal anti-inflammatory drugs; HCC: hepatocellular carcinoma" id="ABBRID0EBGAE">NSAIDs</abbrev> and cancer was done by Kune et al. The report suggests that patients taking <abbrev xlink:title="non-steroidal anti-inflammatory drugs; HCC: hepatocellular carcinoma" id="ABBRID0EFGAE">NSAIDs</abbrev> had a significantly lower incidence of cancer. The positive results of <abbrev xlink:title="non-steroidal anti-inflammatory drugs; HCC: hepatocellular carcinoma" id="ABBRID0EJGAE">NSAIDs</abbrev> in cancer prevention open a new direction in cancer research. The study was done on &gt;1 million subjects with over 30 epidemiological studies; results suggest that <abbrev xlink:title="non-steroidal anti-inflammatory drugs; HCC: hepatocellular carcinoma" id="ABBRID0ENGAE">NSAIDs</abbrev> can be prototypical agents in the prevention of cancer.<sup>[<xref ref-type="bibr" rid="B34">34</xref>,36]</sup> Aspirin is a widely used drug in the world whose major role is in cardiovascular diseases. Multiple trials using aspirin for evaluation of anticancer properties have been done; data suggest that aspirin has approximately 20% to 25% ability to reduce incidence and mortality of several types of cancers. The major beneficial effects were found in the stomach, oesophageal and colorectal cancer. Other <abbrev xlink:title="non-steroidal anti-inflammatory drugs; HCC: hepatocellular carcinoma" id="ABBRID0EYGAE">NSAIDs</abbrev> such as ibuprofen and piroxicam are able to reduce breast and colorectal cancer risk by showing a significant correlation between anti-inflammatory agent use and decreased cancer incidence. The other specific <abbrev xlink:title="cyclooxygenase" id="ABBRID0E3GAE">COX</abbrev>-II inhibitors drugs like rofecoxib and valdecoxib are under clinical investigation, but at the moment, these drugs are used as an adjuvant drugs because of their side effects.<sup>[<xref ref-type="bibr" rid="B37 B38 B39">37–39</xref>]</sup></p>
      </sec>
      <sec sec-type="Corticosteroids" id="SECID0EGHAE">
        <title>Corticosteroids</title>
        <p>Corticosteroids are used as anti-emetic agents to prevent nausea and vomiting driven by cancer chemotherapeutic agents. They are also effective as anti-inflammatory agents in various chronic inflammatory diseases. In the xenograft or experimental model of the breast, colorectal, glioma, and lung cancer. It was observed that pre-treatment with dexamethasone increases the effectiveness of chemotherapy. Dexamethasone was also found to decrease the incidence of lung tumors. The combination of dexamethasone with carfilzomib and lenalidomide had an advantageous effect in multiple myeloma patients.<sup>[<xref ref-type="bibr" rid="B40">40</xref>,41]</sup></p>
      </sec>
      <sec sec-type="Statins, metformin, and embelin" id="SECID0ESHAE">
        <title>Statins, metformin, and embelin</title>
        <p>Statins are used as anti-hyperlipidemic agents, which are also reported for their anti-inflammatory properties. The mechanism involved in the anti-inflammatory activity is due to the reduction of the pro-inflammatory cytokine, macrophage infiltration, and C-reactive protein. Due to additional anti-inflammatory properties, statins can reduce the risk of several cancers which include colorectal cancer, HCC, and breast cancer.<sup>[<xref ref-type="bibr" rid="B42">42</xref>,43]</sup> Metformin, a drug used as an oral hypoglycaemic agent, is also reported as reducing the risk for several cancers, including colon, breast, lung, prostate, ovarian, and pancreatic cancers. Its antineoplastic effect is mediated through activation of the AMPK pathway, which counteracts the protumorigenic effect of hyperinsulinemia, the reduction of systemic glucose concentration, which counteracts the Warburg effect and through its anti-inflammatory properties.<sup>[<xref ref-type="bibr" rid="B44">44</xref>]</sup> Embelin is an isoquinoline derivative reported for its anti-inflammatory properties due to its interference in the arachidonic acid metabolic pathway and can block 5-<abbrev xlink:title="lipooxygenase" id="ABBRID0EGIAE">LOX</abbrev> and PGEs.<sup>[<xref ref-type="bibr" rid="B45">45</xref>]</sup></p>
      </sec>
    </sec>
    <sec sec-type="Natural products" id="SECID0EQIAE">
      <title>Natural products</title>
      <p>Some natural products and foods have anti-inflammatory effects – these include grapes (resveratrol), garlic, and curry powder (curcumin). These compounds have also shown anti-cancer properties due to the induction of apoptosis. These compounds have anti-inflammatory action due to inhibition of the target NF-κB, <abbrev xlink:title="mitogen activated protein kinase" id="ABBRID0EWIAE">MAPK</abbrev>, JNK, <abbrev xlink:title="vascular endothelial growth factor" id="ABBRID0E1IAE">VEGF</abbrev>, and <abbrev xlink:title="cyclooxygenase" id="ABBRID0E5IAE">COX</abbrev> and due to this, they have a role in the anticancer activity.<sup>[<xref ref-type="bibr" rid="B47">47</xref>]</sup> Literature data also suggest that the combination of natural products with chemotherapeutic agents shows beneficial effects. For example, the combination of curcumin with 5-fluorouracil gives synergistic effect while in another study, ginseng saponins were reported to increase the response of cancer cells to chemotherapeutic agents and reduce hematological toxicity after radiation therapy. <sup>[<xref ref-type="bibr" rid="B48">48</xref>]</sup> Berberine act as an anti-inflammatory agent and also has anti-cancer activity. Activity is due to the inhibition of NF-κB and <abbrev xlink:title="cyclooxygenase" id="ABBRID0EQJAE">COX</abbrev>-2 with IC50 value around 0.3 µM.<sup>[<xref ref-type="bibr" rid="B49">49</xref>]</sup></p>
    </sec>
    <sec sec-type="Conclusions" id="SECID0E1JAE">
      <title>Conclusions</title>
      <p>Inflammation and inflammatory pathways play important roles in the development and progression of cancer. Inflammation provides the soil for the development of cancer seeds. Targeting inflammation is one of the good strategies for the prevention of cancer. Anti-inflammatory agents have been shown in experimental, clinical, and epidemiological studies. Currently, FDA-approved anti-inflammatory agents have limited use due to a lack of target specificity and toxicity. Changes in dose regimen or combination of an anti-inflammatory agent with other chemotherapeutic agents or development of new anti-inflammatory agents with target specificity and low side effects may provide the solution. The idea of targeting anti-inflammatory pathways to treat cancer is innovative, but at the same time, a better understanding of biochemical pathways and the development of anti-inflammatory agents with more target specificity with fewer side effects need to be more focused on new effective therapeutic strategies.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <mixed-citation xlink:type="simple">1. Schmidt A, Weber OF. In memoriam of Rudolf Virchow: a historical retrospective including aspects of inflammation, infection and neoplasia. In: Infection and inflammation: impacts on oncogenesis. Contributions to microbiology. Karger Publishers 2006; 13:1–15</mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation xlink:type="simple">2. Singh N, Baby D, Rajguru JP, et al. Inflammation and cancer. Ann Afr Med 2019; 18(3):121–6.</mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation xlink:type="simple">3. Todoric J, Antonucci L, Karin M. Targeting Inflammation in cancer prevention and therapy. Cancer Prev Res (Phila) 2016;9(12):895–905.</mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation xlink:type="simple">4. Meyskens Jr. FL, Mukhtar H, Rock CL, et al. Cancer prevention: obstacles, challenges and the road ahead. J Natl Cancer Inst 2016; 108(2):djv309.</mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation xlink:type="simple">5. Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr 2010; 20(2):87–103.</mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation xlink:type="simple">6. Shi JH, Sun SC. Tumor necrosis factor receptor-associated factor regulation of nuclear factor κB and mitogen-activated protein kinase pathways. Front Immunol 2018; 9:1849.</mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation xlink:type="simple">7. Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci 2019; 20(23):6008.</mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation xlink:type="simple">8. Trikha M, Corringham R, Klein B, et al. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9(13):4653–65.</mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation xlink:type="simple">9. David JM, Dominguez C, Hamilton DH, et al. The IL-8/IL-8R axis: a double agent in tumor immune resistance. Vaccines 2016; 4(3):22.</mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation xlink:type="simple">10. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 2017; 17(9):559–72.</mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation xlink:type="simple">11. Marcuzzi E, Angioni R, Molon B, et al. Chemokines and chemokine receptors: orchestrating tumor metastasization. Int J Mol Sci 2018; 20(1):96.</mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation xlink:type="simple">12. Gonzalez-Avila G, Sommer B, Mendoza-Posada DA, et al. Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. Crit Rev Oncol Hematol 2019; 137:57–83.</mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation xlink:type="simple">13. Joseph C, Alsaleem M, Orah N, et al. Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Res Treat 2020; 182(2):267–82.</mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation xlink:type="simple">14. Szweda M, Rychlik A, Babińska I, et al. Significance of cyclooxygenase-2 in oncogenesis. J Vet Res 2019; 63(2):215–24.</mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation xlink:type="simple">15. Greenhough A, Smartt HJM, Moore AE, et al. The COX-2/PGE 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30(3):377–86.</mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation xlink:type="simple">16. Hashemi Goradel N, Najafi M, Salehi E, et al. Cyclooxygenase-2 in cancer: a review. J Cell Physiol 2019; 234(5):5683–99.</mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation xlink:type="simple">17. Goulet AC, Einsphar JG, Alberts DS, et al. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther 2003; 2(6):713–8.</mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation xlink:type="simple">18. Wang B, Wu L, Chen J, et al. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduct Target Ther 2021; 6(1):94.</mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation xlink:type="simple">19. Ye YN, Wu WK, Shin VY, et al. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005; 26(4):827–34.</mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation xlink:type="simple">20. Kelavkar UP, Nixon JB, Cohen C, et al. Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 2001; 22(11):1765–73.</mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation xlink:type="simple">21. Park MH, Hong JT. Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches. Cells 2016;5(2):15.</mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation xlink:type="simple">22. Liu T, Zhang L, Joo D, et al. NF-κB signaling in inflammation. Signal Transduct Target Ther 2017; 2(1):1–9.</mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation xlink:type="simple">23. Yu H, Lin L, Zhang Z, et al. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther 2020; 5(1):209.</mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation xlink:type="simple">24. Bhandari T, Nizet V. Hypoxia-inducible factor (HIF) as a pharmacological target for prevention and treatment of infectious diseases. Infect Dis Ther 2014; 3(2):159–74.</mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation xlink:type="simple">25. Jun JC, Rathore A, Younas H, et al. Hypoxia-inducible factors and cancer. Curr Sleep Med Rep 2017; 3(1):1–10.</mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation xlink:type="simple">26. Burke SJ, Updegraff BL, Bellich RM, et al. Regulation of iNOS gene transcription by IL-1β and IFN-γ requires a coactivator exchange mechanism. Mol Endocrinol 2013; 27(10):1724–42.</mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation xlink:type="simple">27. Vannini F, Kashfi K, Nath N. The dual role of iNOS in cancer. Redox Biol 2015; 6:334–43.</mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation xlink:type="simple">28. Verhoeven Y, Tilborghs S, Jacobs J, et al. The potential and controversy of targeting STAT family members in cancer. Semin. Cancer Biol 2020; 60:41–56.</mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation xlink:type="simple">29. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011; 75(1):50–83.</mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation xlink:type="simple">30. Murthy D, Attri KS, Singh PK. Phosphoinositide 3-kinase signaling pathway in pancreatic ductal adenocarcinoma progression, pathogenesis, and therapeutics. Front Physiol 2018; 9:335.</mixed-citation>
      </ref>
      <ref id="B31">
        <mixed-citation xlink:type="simple">31. Steven A, Seliger B. Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target. Oncotarget 2016; 7(23):35454–65.</mixed-citation>
      </ref>
      <ref id="B32">
        <mixed-citation xlink:type="simple">32. Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene 2017; 36(11):1461–73.</mixed-citation>
      </ref>
      <ref id="B33">
        <mixed-citation xlink:type="simple">33. Aggarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72(11):1605–21.</mixed-citation>
      </ref>
      <ref id="B34">
        <mixed-citation xlink:type="simple">34. Gunaydin C, Bilge SS. Effects of nonsteroidal anti-inflammatory drugs at the molecular level. Eurasian J Med 2018; 50(2):116–21.</mixed-citation>
      </ref>
      <ref id="B35">
        <mixed-citation xlink:type="simple">35. Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf 2015; 7:31–41.</mixed-citation>
      </ref>
      <ref id="B36">
        <mixed-citation xlink:type="simple">36. Ashish PS, Chhagan NP. Virtual screening of novel hybrid non-steroidal anti-inflammatory drugs (NSAIDs): exploring multiple targeted cancer therapy by an in silico approach. Curr Cancer Ther Rev 2020; 16(1):70–7.</mixed-citation>
      </ref>
      <ref id="B37">
        <mixed-citation xlink:type="simple">37. Magee DJ, Jhanji S, Poulogiannis G, et al. Nonsteroidal anti-inflammatory drugs and pain in cancer patients: a systematic review and reappraisal of the evidence. Br J Anaesth 2019; 123(2):e412–e23.</mixed-citation>
      </ref>
      <ref id="B38">
        <mixed-citation xlink:type="simple">38. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res 2003; 63(18):6096–101.</mixed-citation>
      </ref>
      <ref id="B39">
        <mixed-citation xlink:type="simple">39. Zappavigna S, Cossu AM, Grimaldi A, et al. Anti-Inflammatory Drugs as Anticancer Agents. Int J Mol Sci 2020;21(7):2605.</mixed-citation>
      </ref>
      <ref id="B40">
        <mixed-citation xlink:type="simple">40. Todoric J, Antonucci L, Karin M. Targeting inflammation in cancer prevention and therapy. Cancer Prev Res (Phila.) 2016; 9(12): 895–905.</mixed-citation>
      </ref>
      <ref id="B41">
        <mixed-citation xlink:type="simple">41. Lin K-T, Wang L-H. New dimension of glucocorticoids in cancer treatment. Steroids 2016; 111:84–8.</mixed-citation>
      </ref>
      <ref id="B42">
        <mixed-citation xlink:type="simple">42. Kim S-W, Kang H-J, Jhon M, et al. Statins and Inflammation: New Therapeutic Opportunities in Psychiatry. Front Psychiatry 2019; 10:103.</mixed-citation>
      </ref>
      <ref id="B43">
        <mixed-citation xlink:type="simple">43. Parihar SP, Guler R, Brombacher F. Statins: a viable candidate for host-directed therapy against infectious diseases. Nat Rev Immunol 2019; 19(2):104–17.</mixed-citation>
      </ref>
      <ref id="B44">
        <mixed-citation xlink:type="simple">44. Wang Z, Lai ST, Xie L, et al. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 2014; 106(1):19–26.</mixed-citation>
      </ref>
      <ref id="B45">
        <mixed-citation xlink:type="simple">45. Sheng Z, Ge S, Gao M, et al. Synthesis and biological activity of embelin and its derivatives: an overview. Mini-Rev Med Chem 2020; 20(5):396–407.</mixed-citation>
      </ref>
      <ref id="B46">
        <mixed-citation xlink:type="simple">46. Kashfi K. Anti-inflammatory agents as cancer therapeutics. Adv Pharmacol (San Diego, Calif) 2009; 57:31–89.</mixed-citation>
      </ref>
      <ref id="B47">
        <mixed-citation xlink:type="simple">47. Wang H, Khor TO, Shu L, et al. Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer Agents Med Chem 2012; 12(10):1281–305.</mixed-citation>
      </ref>
      <ref id="B48">
        <mixed-citation xlink:type="simple">48. Tomeh MA, Hadianamrei R, Zhao X. A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci 2019;20(5):1033.</mixed-citation>
      </ref>
      <ref id="B49">
        <mixed-citation xlink:type="simple">49. Gaschott T, Werz O, Steinmeyer A, et al. Butyrate-induced differentiation of Caco-2 cells is mediated by vitamin D receptor. Biochem Biophys Res Commun 2001; 288(3):690–6.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
